Tarlatamab-dlle
Tarlatamab-dlle (Imdelltra) works by bringing healthy T cells (immune cells that help kill cancer cells) and lung cancer cells close together so the T cells can more effectively kill the lung cancer cells. It does this by binding to a protein called CD3 on healthy T cells and a protein called DLL3 on small cell lung cancer cells. Tarlatamab-dlle is a type of immunotherapy drug called a bispecific T-cell engager (BiTE).
FDA label information for this drug is available at DailyMed.
Use in Cancer
Tarlatamab-dlle is approved to treat:
- small cell lung cancer. It is used in adults whose extensive-stage cancer got worse during or after treatment with platinum-based chemotherapy.
Tarlatamab-dlle is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that it provides a clinical benefit in these patients.
More About Tarlatamab-dlle
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Tarlatamab-dlle - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Tarlatamab Shows Promise for Some People with Small Cell Lung Cancer
Targeted Therapy to Treat Cancer
Clinical Trials Accepting Patients
Find Clinical Trials for Tarlatamab-dlle - Check for trials from NCI's list of cancer clinical trials now accepting patients.